Kolexia
Maurina Tristan Médecine générale
Maurina Tristan
Médecine générale
Hôpital Nord Franche-Comté
Montbéliard, France
74 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Néphrocarcinome Carcinomes Tumeurs du rein Métastase tumorale Tumeurs prostatiques résistantes à la castration Anémie Récidive tumorale locale Fatigue

Collaborateurs

Voir plus
Thiery-Vuillemin Antoine
Thiery-Vuillemin Antoine
Le Mittan Annexe Du Hnfc, Montbéliard, France
Mouillet Guillaume
Mouillet Guillaume
Hôpital Jean-Minjoz, Besançon, France
Stein Ulrich
Stein Ulrich
Hôpital Jean-Minjoz, Besançon, France
Sun Xu-Shan
Sun Xu-Shan
Le Mittan Annexe Du Hnfc, Montbéliard, France

Industries

Voir plus
Ipsen
3 collaboration(s)
Dernière en 2023
Sanofi
3 collaboration(s)
Dernière en 2020
Janssen
3 collaboration(s)
Dernière en 2023
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
VolATIL: A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers
Essai Clinique (CHU Besançon)   25 mai 2023
SPICI: Strategic Treatment Pause of First-line Immune Check Point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in Good or Only One Adverse Prognostic Factor in Intermediate Risk Metastatic Renal Cell Carcinoma (mRCC) With an Objective Response: a Randomised, Non-inferiority Phase III Study
Essai Clinique (CHU Bordeaux)   10 mars 2023
PEACE2: A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Essai Clinique (Sanofi)   28 octobre 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T 1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.
Frontiers in oncology   19 juillet 2022
Evaluation of drug-drug interactions among patients with metastatic prostate cancer in routine care.
2022 ASCO Genitourinary Cancers Symposium   16 février 2022
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study.
2022 ASCO Genitourinary Cancers Symposium   16 février 2022
Évaluation médico-économique des immunothérapies anti-cancéreuses: analyse de la littérature
Journées dermatologiques de Paris, 30 novembre - 4 décembre 2021   01 décembre 2021
SURF: Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Essai Clinique (Pfizer)   17 novembre 2021
Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.
2021 Genitourinary Cancers Symposium   02 mars 2021
1878P Health-related quality of life (HRQoL) assessment for patients with advanced renal cell carcinoma (aRCC) treated with a tyrosine kinase inhibitor (TKI) using electronic patient reported outcomes in daily clinical practice: QUANARIE trial
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020